AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalized patients in a late-stage study, the British drugmaker said on Monday.
The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50 percent in patients who had been symptomatic for seven days or less, meeting the main goal of the trial.
“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.
The company will discuss the data with health authorities, it added, without elaborating.
AstraZeneca is also developing the drug cocktail as a therapy to protect people who do not have a strong enough immune response to COVID-19 vaccines. It requested emergency approval from US regulators for its use as a prevention drug last week.
Saudi Arabia signs MoUs with COVID-19 vaccine makers Pfizer, AstraZenecaSaudi Arabia has signed two Memorandums of Understanding (MoUs) with COVID-19 vaccine makers Pfizer and AstraZeneca to promote investment in the ... Coronavirus
AstraZeneca boss Soriot says do not rush needlessly into COVID-19 jab booster: ReportAstraZeneca Plc Chief Executive Pascal Soriot said booster COVID vaccine doses may not be needed for everyone in Britain and rushing into a nationwide ... Coronavirus
AstraZeneca, EU reach settlement on delivery of remaining COVID-19 vaccinesThe European Commission and AstraZeneca said on Friday they had reached a settlement on delivering remaining COVID-19 vaccine doses by the British ... Coronavirus